FAQ: Tonix Pharmaceuticals Added to Russell 3000 and 2000 Indexes
Summary
What does Tonix Pharmaceuticals’ inclusion in the Russell 3000 and 2000 Indexes signify?
It signifies Tonix Pharmaceuticals’ market cap growth and enhances the company’s visibility among investors as it moves closer to potential FDA approval and commercialization of its fibromyalgia treatment, TNX-102 SL.
Why is Tonix Pharmaceuticals’ addition to the Russell indexes important?
The addition is important because Russell indexes are widely used benchmarks with $10.6 trillion in assets tied to their performance, which can increase investor interest and confidence in Tonix Pharmaceuticals.
How does Tonix Pharmaceuticals’ inclusion in the Russell indexes affect its visibility?
Inclusion boosts Tonix’s visibility among investors and the broader financial community, potentially attracting more investment as the company progresses toward commercialization of its products.
What is TNX-102 SL, and what is its significance to Tonix Pharmaceuticals?
TNX-102 SL is Tonix Pharmaceuticals’ product candidate for managing fibromyalgia, which has completed two statistically significant phase 3 studies and has been granted Fast Track designation by the FDA, representing a significant milestone in the company’s pipeline.
When will Tonix Pharmaceuticals submit a New Drug Application for TNX-102 SL?
Tonix Pharmaceuticals plans to submit a New Drug Application to the FDA this month for TNX-102 SL for the management of fibromyalgia.
What other developments are part of Tonix Pharmaceuticals’ portfolio?
Tonix’s portfolio includes TNX-4200 for antiviral treatments, TNX-1300 for cocaine intoxication, TNX-1500 for preventing allograft rejection and treating autoimmune diseases, and commercial products for acute migraine treatment.
Where can I find more information about Tonix Pharmaceuticals?
More information about Tonix Pharmaceuticals can be found on their official website at www.TonixPharma.com or in the company’s newsroom at https://ibn.fm/TNXP.
What is the significance of the FDA’s Fast Track designation for TNX-102 SL?
The FDA’s Fast Track designation for TNX-102 SL accelerates the review process for drugs that treat serious conditions and fill an unmet medical need, highlighting the potential importance of TNX-102 SL in managing fibromyalgia.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 93638